6.3 Intravesical Chemotherapy & BCG Immunotherapy

6.3 Intravesical Chemotherapy & BCG Immunotherapy

Adjuvant intravesical therapy is essential to reduce the substantial risks of recurrence and progression following complete TURBT in non-muscle-invasive bladder cancer (NMIBC). Clinical strategies divide broadly into two categories: intravesical chemotherapy (a single immediate instillation for eligible papillary disease, or adjuvant courses mainly for intermediate risk) and intravesical Bacillus Calmette-Guérin (BCG) immunotherapy (standard bladder-preserving treatment for high risk and selected very high risk after discussion of cystectomy).

---

1. Immediate Single Post-Operative Instillation (SI) of Chemotherapy

Biological Rationale and Clinical Evidence

TURBT inevitably dislodges viable neoplastic cells into the irrigating fluid. These circulating cells readily implant onto traumatized urothelial basement membrane and resection crater sites. Concurrently, microscopic residual tumor cells at the surgical margins may persist.

• An immediate single instillation of cytotoxic chemotherapy destroys free-floating cells and ablates residual microscopic clonogenic foci.
• Efficacy: EAU cites an individual-patient meta-analysis showing five-year recurrence 59%→45%, an absolute reduction of 14 percentage points. Benefit was seen in primary tumours and selected recurrent intermediate-risk tumours with low prior recurrence rate/low EORTC recurrence score; SI alone is insufficient for many higher-recurrence-risk patients.
• Timing: Give SI within 24 hours, as soon as safely feasible and preferably in the first two hours. Early treatment targets implantation before cells become firmly attached/covered by extracellular matrix.

Chemotherapeutic Agents

• Mitomycin C (MMC): 40 mg dissolved in 20–40 mL of sterile water or normal saline, retained in the bladder for 1 to 2 hours.
• Epirubicin: 50–80 mg in 50 mL sterile water.
• Gemcitabine: 1,000–2,000 mg in 50–100 mL saline. An immediate gemcitabine instillation reduced recurrence versus saline with low toxicity in SWOG S0337. There is no randomized SI comparison establishing equivalence or universal superiority over MMC.

Absolute Contraindications to Immediate Instillation

1. Documented or Suspected Bladder Perforation: Extraperitoneal or intraperitoneal extravasation of cytotoxic chemotherapy causes severe perivesical fat necrosis, retroperitoneal phlegmon, intractable pelvic fibrosis, enterovesical or vesicocutaneous fistulae, and potentially fatal systemic myelosuppression.
2. Bleeding Requiring Bladder Irrigation: Omit SI; ongoing bleeding and extensive resection raise absorption/extravasation concerns and irrigation prevents effective drug retention.
3. Extensive Deep Resection: Extensive resection near the perivesical fat carries high risk of occult microperforation.

---

2. Adjuvant Chemotherapy for Intermediate-Risk Disease & Optimization

For intermediate-risk NMIBC, induction intravesical chemotherapy, with or without maintenance for up to one year, reduces recurrence and usually causes fewer adverse effects than BCG:

• Example Schedule: Six weekly induction instillations, with monthly maintenance if selected. The optimal schedule and maintenance benefit remain uncertain; EAU advises not exceeding one year.
• Pharmacokinetic Optimization of Mitomycin C:
  • Urine Alkalinization: MMC is less stable in acidic urine. The Au 2001 optimized regimen used sodium bicarbonate 1.3 g the night before, morning of and 30 minutes before treatment; alkalinization helps preserve active drug, rather than guaranteeing one pH target in every patient.
  • Fluid Restriction: The optimized trial restricted drinking for eight hours before and during treatment to reduce urine production and dilution. Apply an appropriate local protocol.
  • Complete Bladder Emptying: Residual urine is completely drained via catheter before instilling the drug.
  • Bundled Optimization: Au 2001 compared 40 mg/20 mL plus alkalinization, low residual urine and fluid restriction with 20 mg/20 mL without these manipulations. Better recurrence control supports the bundle, not an isolated proof that 40 mg/20 mL is superior to 40 mg/40 mL.
• Device-Assisted Chemotherapy:
  • Radiofrequency-Induced Chemohyperthermia (RF-CHT) and Hyperthermic Intravesical Chemotherapy (HIVEC): Heating the bladder mucosa to 41–43°C increases urothelial permeability, inhibits DNA repair mechanisms, and enhances MMC cytotoxicity.
  • Electromotive Drug Administration (EMDA): Uses an electrical current to enhance MMC transport across the urothelium.

---

3. Intravesical Bacillus Calmette-Guérin (BCG): Mechanism & Immunology

Bacillus Calmette-Guérin is a live, attenuated strain of Mycobacterium bovis. Maintenance BCG is more effective than chemotherapy for recurrence prevention. Evidence also supports reduced progression versus mixed control treatments, but a progression/survival advantage over MMC was not confirmed in the individual-patient meta-analysis; distinguish recurrence from progression endpoints.

+-------------------------------------------------------------------------------+
|                      BCG IMMUNOLOGICAL CASCADE IN THE BLADDER                 |
+-------------------------------------------------------------------------------+
|  1. Intraluminal Instillation of Live Attenuated Mycobacterium bovis          |
|                                    v                                          |
|  2. Urothelial Attachment via Fibronectin Attachment Protein (FAP)            |
|     - Binds exposed basement membrane fibronectin in resection bed            |
|                                    v                                          |
|  3. Internalization into Urothelial & Carcinoma Cells via Macropinocytosis    |
|                                    v                                          |
|  4. Massive Cytokine & Chemokine Release:                                     |
|     - IL-1, IL-2, IL-6, IL-8, IL-12, IFN-gamma, TNF-alpha, GM-CSF           |
|                                    v                                          |
|  5. Recruitment of Effector Immune Infiltrate:                                |
|     - CD4+ Helper T cells (Th1 polarization) & CD8+ Cytotoxic T Lymphocytes   |
|     - Natural Killer (NK) cells, Macrophages, Granulocytes                    |
|                                    v                                          |
|  6. Target Cell Lysis: MHC Class I/II presentation, Perforin/Granzyme-mediated|
|     destruction of neoplastic urothelium & granuloma formation                |
+-------------------------------------------------------------------------------+

Key Phases of the Immune Cascade

1. Fibronectin Binding: BCG express fibronectin attachment protein (FAP), which binds avidly to fibronectin deposited on traumatized urothelial basement membranes.
2. Cellular Internalization: BCG is internalized by normal and malignant urothelial cells via macropinocytosis.
3. Th1-Polarized Cytokine Response: Ingestion stimulates the release of pro-inflammatory cytokines: Interleukin-2 (IL-2), Interleukin-12 (IL-12), Interferon-gamma (IFN-γ), and Tumor Necrosis Factor-alpha (TNF-α). A robust Th1 cytokine profile correlates with successful clinical response.
4. Cytotoxic Effector Lysis: Activated CD8+ cytotoxic T lymphocytes and NK cells recognize tumor antigens and eliminate residual microscopic cancer cells, accompanied by suburothelial non-caseating granuloma formation.

---

4. BCG Treatment Schedules: Induction & Maintenance

Do not give BCG during the first two weeks after TURBT; defer further if mucosal injury, visible haematuria or symptomatic infection persists. Healing limits systemic absorption of live mycobacteria.

Induction Course (Morales Regimen)

• Consists of 6 consecutive weekly intravesical instillations.
• Maintenance is required for optimal efficacy; induction alone has less reliable recurrence control.

Maintenance Protocols: The SWOG Regimen

The Southwest Oncology Group (SWOG 8507 / Lamm protocol) established the therapeutic standard:

• 3 weekly instillations administered at months 3, 6, 12, 18, 24, 30, and 36 (total of 27 instillations over 3 years).
• Duration by Risk Group:
  • High-Risk NMIBC: Full-dose BCG for one to three years. Three years improves recurrence control versus one year, without demonstrated progression or overall-survival improvement; balance added treatment against toxicity and access.
  • Intermediate-Risk NMIBC: If BCG is chosen, one year (induction plus three-week boosters at 3, 6 and 12 months); longer maintenance has not shown additional benefit in this group.
• Dose Reduction for Toxicity: Reduced-dose BCG may lessen adverse effects, but can increase recurrence and does not consistently reduce toxicity. Do not promise preserved efficacy; consider symptom severity, risk, postponement and available treatment with the patient.

---

5. Adverse Effects & Management of BCG Toxicity

Up to 70–80% of patients experience some degree of adverse reaction during BCG therapy. Distinguishing expected local immune inflammation from life-threatening systemic mycobacterial dissemination is critical.

Local Toxicities

• Chemical / Immune Cystitis: Dysuria, urinary frequency, urgency, and low-grade pyuria occurring within 24–48 hours of instillation.
  • Management: Symptom-directed treatment such as mirabegron, phenazopyridine or NSAIDs. If symptoms persist or worsen, postpone BCG, obtain urine culture and evaluate/treat infection; do not substitute automatic dose reduction for assessment.
• Haematuria: Often transient, but visible blood requires postponing BCG. Investigate persistent bleeding, including cystoscopy to exclude tumour; microscopic haematuria alone is not a contraindication.

Severe Local and Systemic Complications (BCGitis)

Absolute Contraindications to BCG Instillation

• Prior systemic BCG sepsis or severe hypersensitivity reaction.
• Active, gross hematuria (indicates disrupted vascular barrier).
• Traumatic or difficult catheterization (catheter-induced mucosal tear).
• During the first two weeks after TURBT, or while traumatic mucosal injury remains unhealed.
• Symptomatic UTI. Asymptomatic bacteriuria, leukocyturia and microscopic haematuria alone do not preclude BCG.

Immunosuppression: EAU treats it as a relative contraindication requiring specialist assessment; severe immunodeficiency may preclude a live BCG product under its prescribing information. Transplant status or HIV infection alone should not be equated to a universal absolute prohibition.

---

6. Definitions of BCG Failure: EAU Consensus

Recognizing BCG failure is crucial because continuing ineffective intravesical therapy in high-grade disease delays life-saving radical cystectomy. The EAU categorizes BCG failure into distinct clinical entities:

1. BCG-Refractory:
   • T1 HG/G3 at the three-month assessment.
   • Persistent Ta HG/G3 after further BCG (re-induction or first maintenance), assessed at three/six months.
   • CIS at three months persisting at six months after re-induction or first maintenance; CIS at three months after induction alone can still respond to another course.
   • HG tumour appearing during maintenance.
2. BCG-Relapsing: HG recurrence after an initial response and completion of maintenance. The clinically important early-relapse windows differ by disease type: six months for Ta/T1 HG, twelve months for CIS.
3. BCG-Unresponsive: All refractory tumours, plus Ta/T1 HG recurrence within six months or CIS within twelve months of completing adequate BCG.
   • Adequate BCG: At least 5/6 induction doses, plus 2/6 doses of a second induction or 2/3 maintenance doses.
4. BCG-Exposed: HG disease after BCG that does not meet unresponsive criteria, including Ta HG/CIS at three months after induction alone or selected delayed relapses. Additional BCG may benefit selected patients.
5. BCG-Intolerant: Severe adverse effects prevent completion of treatment.

LG recurrence is not BCG failure. Any progression to muscle-invasive disease requires management on the invasive-cancer pathway rather than another NMIBC instillation algorithm.

---

7. Management of BCG-Unresponsive Disease

BCG-unresponsive tumours are unlikely to benefit from further BCG. Assess restaging and timely definitive treatment rather than assigning one progression percentage to heterogeneous patients or persisting with ineffective instillations.

• Standard of Care: Immediate Radical Cystectomy (RC):
  • Radical cystectomy with bilateral pelvic lymphadenectomy is the primary therapeutic benchmark endorsed by EAU and international consensus guidelines.
  • Arrange cystectomy promptly when selected; progression before definitive surgery can worsen prognosis.
• Bladder-Sparing Salvage Strategies (Strictly for patients unfit for or adamantly refusing RC):
  • Pembrolizumab: Intravenous anti-PD-1 immune checkpoint inhibitor; FDA-approved, without a current EMA NMIBC indication, for BCG-unresponsive high-risk CIS with/without papillary tumours when cystectomy is declined or unsuitable. KEYNOTE-057 showed 41% complete response at three months; 46% of responders maintained response for at least 12 months, approximately 19% of the full efficacy cohort.
  • Nadofaragene Firadenovec: Non-replicating adenoviral vector delivering human interferon-alpha-2b cDNA directly into urothelial cells. The phase III single-arm trial found 53.4% CIS complete response within three months; 45.5% of those responders remained free of HG recurrence at twelve months. FDA-approved; conditional EU authorisation was granted on 28 May 2026 for BCG-unresponsive CIS with/without papillary tumours.
  • Sequential Intravesical Chemotherapy: Dual intravesical gemcitabine and docetaxel administered sequentially has predominantly retrospective evidence; one BCG-unresponsive cohort reported 65% and 49% HG recurrence-free survival at twelve and 24 months. It is an option when cystectomy is declined or unsuitable, not proof of equivalent long-term cancer control to surgery.
  • Device-Assisted Chemotherapy: Radiofrequency-induced chemohyperthermia (RF-CHT) with MMC.

---

8. Intravesical Instillation Protocols & BCG Toxicity Management Comparison Table